跳至主要内容
临床试验/EUCTR2004-000053-34-CZ
EUCTR2004-000053-34-CZ进行中(未招募)不适用

Comparison of continuous combined estrogen-progestin regimen in alleviation of estrogen deficiency symptoms of postmenopausal women. A randomized, double-blind, fixed dose, multicentre phase IIIb study of 12 month

Orion Corporation, Orion Pharma, Orionintie,0 个研究点目标入组 675 人开始时间: 2004年10月11日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
675

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • signed and dated IC
  • Postmenopausal women: = 12 months of spontaneous amenorrhoea or = 6 weeks post-surgical bilateral oophorectomy without hysterectomy at screening
  • = 30 moderate to severe hot flushes per week at baseline and/or vasomotor symptoms requiring treatment according to clinical judgement of the investigator
  • Wash-out period
  • -is not needed or
  • -of 1 wk or longer for prior vaginal hormonal products (rings, creams, gels)
  • -of 4 wks or longer for prior transdermal estrogen alone or estrogen/progestin products
  • -of 4 wks or longer for prior oral estrogen and/or estrogen/progestin therapy
  • -of 8 wks or longer for prior intrauterine progestin therapy
  • -of 3 months or longer for prior progestin implants and estrogen alone injectable drug therapy
  • -of 6 months or longer for prior estrogen pellet therapy or progestin injectable drug therapy
  • no pathological findings in mammogram obtained within 6 months of screening visit
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 36 months of spontaneous amenorrhea at screening
  • pregnancy or breastfeeding
  • known or past endometrial hyperplasia or cancer
  • known, past, or suspected estrogen-dependent malignant tumours (e.g. breast cancer)
  • cervical smear class III-IV according to the Bethesda classification
  • undiagnosed uterine bleedings
  • previous idiopathic or current venous thromboembolism (deep venous thrombosis, pulmonary embolism)
  • active or recent arterial thromboembolic disease (e.g. angina pectoris, myocardial infarction)
  • personal or strong family history of thromboembolism or recurrent (= 3) spontaneous abortions
  • heart failure (NYHA class III-IV)
  • cerebrovascular accidents, stroke or transient ischemic attacks in the subject history
  • serious disorders of blood coagulation system
  • acute liver disease or a history of liver disease (including cholelithiasis) with clinically significant abnormalities in liver function tests at baseline
  • uterine fibroids
  • endometriosis
  • known hypersensitivity to any component of the preparations
  • uncontrolled or poorly controlled hypertension (diastolic BP > 95 mmHg and/or systolic BP > 160 mmHg) despite of antihypertensive treatment
  • severe or uncontrolled thyroid disease, e.g. thyreotoxicosis
  • impaired renal function with clinically significant elevated serum creatinine concentration
  • insulin-dependent diabetes mellitus
  • diagnosed psychiatric disorders (e.g. schizophrenia, depression)
  • systemic lupus erythematosus (SLE)
  • any other treatment for climacteric symptoms
  • any treatment for hyperlipidemias
  • any treatment affecting sex hormone system (e.g. phytoestrogens like soya)
  • suspected alcohol or drug abuse
  • suspected poor compliance
  • participation in another clinical study within the previous 60 days or during the study
  • clinically significant abnormalities in the laboratory assessments at baseline

研究者

发起方
Orion Corporation, Orion Pharma, Orionintie,

相似试验

Comparison of continuous combined estrogen-progestin... | 临床试验